Review

Koschei the immortal and anti-aging drugs

MV Blagosklonny*,¹

In Slavic folklore, Koschei the Immortal was bony, thin and lean. Was his condition caused by severe calorie restriction (CR)? CR deactivates the target of rapamycin pathway and slows down aging. But the life-extending effect of severe CR is limited by starvation. What if Koschei's anti-aging formula included rapamycin? And was rapamycin (or another rapalog) combined with commonly available drugs such as metformin, aspirin, propranolol, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors.

Cell Death and Disease (2014) 5, e1552; doi:10.1038/cddis.2014.520; published online 4 December 2014

Facts

- Calorie restriction deactivates mTOR and increases life span
- Rapamycin prevents obesity and extends life span
- In fairy tales, long-lived heroes were lean, slim and bony

Open Questions

- Were their leanness and longevity due to genetic inhibition of mTOR?
- Can leanness plus longevity be achieved by rapamycin?
- How to combine five clinically available anti-aging drugs with calorie restriction?

Koschei the deathless (a villain in Russian, Polish and Ukrainian fairy tales) was immortal, strong, bony and lean (Figure 1). Was it his passion for the young princess Vasilisa, the Beautiful, who rendered him immortal? Did he lose his appetite because of his tragic love? Or was he secretly taking a rapalog such as rapamycin (Sirolimus), Temsirolimus, Everolimus and Deforolimus. And did Koschei benefit from benevolent glucose intolerance? Or, in contrast, was he insulin hypersensitive? Here are some answers and subsequent questions.

Rapamycin Prevents Obesity

In mice on high-fat diet, rapamycin decreases obesity and prevents weight gain.^{1–4} In rats, rapamycin (3 times per week) decreased age-associated weight gain.⁵ Also, chronic (every-day) treatment with rapamycin reduces adiposity and body weight.^{6,7} (In some strains, chronic daily treatment was associated with insulin resistance (IR), but more on that latter). In humans, rapamycin decreases the size of fat cells (adipocytes) and body weight.⁵ In humans, kidney transplantation is associated with weight gain, which is preventable by rapamycin.⁸ So, at least at high doses, rapamycin can

decrease weight gain in mice, rats and humans. Yet, Koschei was unusually skinny and there is no data that rapamycin can cause such a severe weight loss.

How Rapamycin Prevents Obesity

- Rapamycin increases lipolysis, releasing fatty acids from the fat tissue.^{9–12}
- Rapamycin prevents entry of lipoproteins into the tissues.⁶
- Rapamycin decreases insulin secretion, therefore, preventing insulin-induced obesity.¹³
- Rapamycin prevents adipocyte differentiation.^{10,14–16}

Rapamycin increases lipolysis and decreases, this can lead to hyperlipidemia (see for explanation schema 2 in¹⁷). Hyperlipidemia (or dyslipidemia) is a biomarker of the treatment with high doses of rapamycin and evirolimus.⁹ Rapalog-induced dyslipidemia is a benevolent sign of therapeutic effects. In fact, rapamycin prevents atherosclerosis.^{18–20}

Hyperlipidemia is rapidly reversible.²¹ Eventually, hyperlipidemia disappears despite chronic use of rapamycin.²² Noteworthy, hyperlipidemia can be diminished by lipid-lowering drugs, as shown in renal transplant patients who were receiving rapamycin.²³

Fatty acids are burned by the muscles (especially during physical exercise) and also incorporated into lipoproteins by the liver.

We can hypothesize that benevolent dyslipidemia can be diminished by the following:

- Physical exercise (the muscle burns lipids).
- Calorie restriction.

These two predictions need to be tested.

¹Department of Cell Stress Biology, Roswell Park Cancer Institute, BLSC, L3-312, Elm and Carlton Streets, Buffalo, NY, USA

*Corresponding author: MV Blagosklonny, Department of Cell Stress Biology, Roswell Park Cancer Institute, BLSC, L3-312, Elm and Carlton Streets, Buffalo 14263, NY, USA. Tel: +1 716 8458086; Fax: +1 716 8453944; E-mail: blagosklonny@oncotarget.com

Received 16.10.14; revised 01.11.14; accepted 03.11.14; Edited by G Melino

Figure 1 Koshechey the Deathless by Ivan Bilibin, 1901

mTOR Causes Obesity and IR. Mammalian target of rapamycin (mTOR) is a nutrient-sensing pathway.^{24–31} Nutrients such as glucose, amino and fatty acids activate mTOR and also increase insulin, which also activates mTOR. In the fat tissue, mTOR promotes adipocyte differentiation and hypertrophy, increases lipogenesis (synthesis of triglycerides) and decreases lipolysis (hydrolysis of triglycerides), leading to fat accumulation or obesity. In a vicious cycle, obesity activates mTOR.^{32,33}

To limit its overactivation, mTOR blocks insulin signaling, causing IR.^{34–39} Rapamycin and calorie restriction (CR) can reverse IR.^{32,34,40–49} For example, in healthy men, infusion of amino acids activates mTOR causing IR.^{44,46} Administration of 6 mg rapamycin before amino acids prevents IR.⁴⁶ Noteworthy, IR and metabolic syndrome are multifactorial.^{50–61}

The Misunderstood Effect: Benevolent IR

The most common argument against rapamycin is that it causes IR. Somehow, this is the only rumor that many scientists heard about rapamycin. In fact, glucose intolerance and IR was observed in a few strains of rodents treated daily with high doses of rapamycin.^{2,62–64} Yet, this was not detrimental for animal health. In contrast, IR was associated with weight loss and/or extended life span. Furthermore, unlike C57BL/6 mice,⁶⁴ genetically heterogeneous HET3 mice on a rapamycin diet were glucose intolerant but insulin sensitive.⁶⁵ Ironically, although believing that rapamycin is dangerous, most scientists do not know the difference between glucose intolerance and IR. They know even less about classic conditions of spectacular glucose intolerance and IR. Claude Bernard (19th century) described that during starvation humans and dogs develop reversible starvation-diabetes.⁶⁶ If a starved animal (or human) consumes sugar, this sugar will appear in the urine, forcing water to follow (polyuria). The word ‘diabetes’ means an increased amount of urine (polyuria). And ‘mellitus’ means sweet. This sweet taste had been noticed in the urine by the ancient Greeks. So starvation is accompanied by the most definitive symptom of ‘diabetes mellitus’. This is a reversible condition to cope with starvation.

Figure 2 Insulin-resistance: two opposite conditions. Insulin resistance (IR) can be caused by the activation of mTOR and, paradoxically, by mTOR inhibition. In the first case, IR is detrimental for health, whereas in the second case it is benevolent.^{13,66,67}

Why Starvation Is Manifested by Benevolent Pseudodiabetes?

During fasting, lipolysis is increased providing the ‘fuel’ (free fatty acids and glycerol) for the peripheral tissues. The brain depends on glucose (and ketones). In the liver, amino acids are converted into glucose (gluconeogenesis) and fatty acid into ketones. To spare glucose for the brain, insulin secretion is inhibited and peripheral tissues become insulin resistant. Low insulin levels and IR are manifested as glucose intolerance: if a starved person consumes glucose, it is not metabolized by the tissues, its blood levels rose and glucose appears in the urine. Also, the liver produces ketones from lipids (to feed the brain). Production of ketones is a hallmark of type I diabetes. Starvation-induced pseudodiabetes is benevolent because they are associated with inhibited mTOR.⁶⁷ In contrast, in the modern time, IR (as we know it) is associated with obesity and leads to diabetes type II.^{40,13} This harmful IR is associated with over-activation of mTOR and aging (Figure 2).

Calorie Restriction

CR extends life span in numerous species from worm to mammals.^{11,28,68–81} CR prevents age-related diseases including cancer and sarcopenia.^{82–84} Whereas moderate CR increases insulin sensitivity, severe CR causes signs of IR.⁸⁵ Among individuals who had been practicing severe CR, 40% of CR individuals showed ‘diabetic-like’ glucose intolerance.⁸⁵ In theory, starvation would be beneficial for health, but cannot last long enough for obvious reason – death from starvation. But high doses of rapamycin can mimic severe CR without actual nutrient deficiency, thus lacking harmful effects of starvation.

Koschei Was not Starved

Definitely, Koschei was not starved. He was bonny and strong and this is not compatible with starvation. Fasting that is manifested by ‘diabetes’ (sugar in the urine) cannot last too long to extend life span but rapamycin can. And since rapamycin does not decrease food consumption, it may

extend life span dramatically, while moderately preventing obesity. Importantly, rapamycin increases skeletal muscle and bone mass.⁸⁶ Given that Koschei was deathless, healthy, strong (muscular) and bony, he perhaps used CR-mimetic such as rapamycin, rather than severe CR.

Rapamycin Plus Moderate CR

Because rapamycin inhibits mTOR but not food consumption, rapamycin is expected to disproportionally increase life span compared with its moderate effects on body weight. For example, at low doses and frequencies, which do not cause IR and other metabolic alterations, rapamycin still extends life span in mice.⁸⁷ As we discussed, acute treatment by rapamycin increases insulin sensitivity. Pulse (intermittent) treatment with rapamycin (either once a week or every other week or intermittent short courses) extends life span,^{88–93} while maintaining insulin sensitivity.⁸⁷ In high-fat diet-fed C57BL/6 mice, weekly rapamycin for 22 weeks improved metabolic and immune status. Rapamycin-treated mice were leaner and were protected against IR and mTORC2 activity was intact.⁴ So, life extension by rapamycin can be associated with either IR or insulin sensitization depending on the dose and the frequency of administration. The life extension and anticancer effects were detectable at low-frequency administration, when little effect on weight was observed. Yet Koschei was extraordinary lean. We can consider two scenarios. First, he might use very high doses of rapamycin to develop ‘starvation-like diabetes’, which can be followed by weight loss. (Note: weight loss is a symptom of type I diabetes). Although high chronic doses of rapamycin in some strains of mice cause IR, this IR did not reach the magnitude of full-blown ‘pseudodiabetes mellitus’. According to second scenario, Koschei combined rapamycin with standard CR (not starvation). We can expect that this will both extend life span and eliminate fat tissue. In agreement with second scenario, Koschei was known to be greedy, so CR was naturally added to rapamycin. And he should not experience diabetic-like polyurea because he did not eat sweets or sugar, but instead his diet consisted from small amount of meat (human), fish (mermaid) and fresh vegetables (nettle).

Once Again on Benevolent IR

In contrast, starvation/rapamycin-induced IR is associated with inhibited mTOR (Figure 1). In all animal models, IR coupled with low mTOR is associated with health and life span extension.⁶⁷ Is benevolent IR and pseudodiabetes a goal of rapamycin treatment for maximal life span extension? Or, in contrast, this should be avoided? In other words, should we use high doses of rapamycin daily or pulse (intermittent) treatment.

Apart from the question whether rapamycin-induced IR is benevolent or not, it is unclear what is its exact mechanism. In different studies, IR was accompanied either by low or high insulin levels. In some studies, IR was associated with low activation of Akt by insulin,^{64,94} whereas in other studies rapamycin promoted IR despite normal activation of the Akt axis.⁶ In cell culture, rapamycin reverses IR caused by glucose and does not cause IR even at chronic (2 weeks) use.⁹⁵

Thus, details of rapamycin-induced IR are still unclear. What is clear is that at both high and low doses, at chronic and intermittent administrations, rapamycin extends life- and health-span in mice. Also, it was taken by millions of humans in high doses daily, even though transplant and cancer patients were in bad health to start with. The most noticeable side effects of rapalogs (rapamycin, temsirolimus, everolimus) are prevention of cancer^{96–98} and regression of heart hypertrophy in kidney transplant recipients.⁹⁹ Rapalogs are anticancer drugs.^{100–109}

Rapalogs as Anti-aging Drugs

Nutrients activate mTOR pathway, which drives cellular growth and functions, and then geroconversion and hyperfunctions.¹¹⁰ On organismal level, mTOR drives growth early in life and aging later in life.^{111,112} Rapamycin slows aging and extends life span in mice.^{113–121} What is the cellular mechanism that allows rapamycin to slow organismal aging? Rapamycin slows down geroconversion: conversion from quiescence to irreversible senescence.^{122–130} Senescence is characterized by cellular hyperfunction (hyper secretion, hypertrophy, pro-inflammation and so on).^{131–136} This cellular hyperfunction also cause a feedback signal resistance (such as IR) to limit hyperfunctions. A combination of hyperfunctions and signal resistance leads to alterations in homeostasis and initiates age-related diseases such as obesity, atherosclerosis, hypertension, neurodegeneration, osteoporosis, sarcopenia.^{30,119,137,138} Cancer is preventable by rapamycin.^{88,90,91,96–98,136,139–146} Rapamycin prevents age-related diseases in rodents from macular degeneration and obesity to cancer and heart dysfunction.^{142,146,147–152} Rapamycin also extends life span in normal and cancer-prone mice as well as in mice with premature aging syndromes.^{93,153} In the latter case, rapamycin at an average extended life span more 100% and maximal survival > 300%.¹⁵³

The Anti-aging Formula

Koschei was constantly fighting with enemies. So physical exercise was a part of his daily life. Mobilized by rapamycin, lipids can be burned by the muscle during physical exercise. By itself, chronic physical exercise inhibits mTOR and increases insulin sensitivity.¹⁵⁴ Thus, rapamycin was combined with moderate CR (based on vegetables and fish) and physical exercise.

There are several clinically approved, widely used drugs that could be added to the rapamycin CR/exercise combination. They include metformin, aspirin, inhibitors of angiotensin II and propranolol.

It was shown almost 50 years ago that phenformin and metformin, anti-diabetic drugs that improve IR, also slow down aging and prevent cancer in rodents.^{100,106,155–163} These effects were explained from the mTOR perspective, revealing a rationale to combine rapamycin and metformin.¹⁶⁴ Two agents may even cancel each other side effects. For example, whereas metformin can increase lactate production, rapamycin decreases it.¹⁶⁵ Metformin also prevents cancer and other age-related diseases in humans.^{166–174}

Aspirin, an anti-inflammatory agent, decreases pro-inflammation, a marker of senescence, as well as inhibits hyperfunctions of blood platelets and endothelial cells.^{133,175,176} There is increasing evidence that aspirin is beneficial in the prevention of multiple age-related diseases and their complications.^{177–184} Aspirin increases life span of genetically heterogeneous male mice¹⁷⁹ and even in the worm *Caenorhabditis elegans*.¹⁸⁵

Angiotensin II activates mTOR pathway¹⁸⁶ and is involved in aging and age-related diseases in mammals.^{187,188} Disruption of the Ang II type 1 receptor promotes longevity in mice. At 29 months, when all wild-type animals died, 85% mice lacking the receptor were still alive. These remaining AT1 –/– mice lived for an additional 7 months, with life span 26% longer than controls.¹⁸⁹ Angiotensin II receptor blockers (ARB) (Valsartan, Telmisartan, Losartan) as well as angiotensin-converting enzyme inhibitors (Captopril, Lisinopril, Enalapril, Ramipril) are widely used as therapy for hypertension. Long-term angiotensin-converting enzyme inhibition or ARB doubles life span of hypertensive rats.^{190,191} In healthy (normal blood pressure) rats, long-term enalapril treatment decreases body weight gain and prolonged life span.¹⁹² Long-term use of ARBs is associated with a lower incidence of cancer occurrence, thereby suggesting that ARBs may prevent cancer development.¹⁹³

Propranolol, a non-selective beta-adrenergic blocker, is widely used to treat hypertension and ischemic heart disease. In addition, propranolol prevents cancer^{194–197} and hepatic steatosis.¹⁹⁸ Also, berberine and statins¹⁹⁹ can be included into the anti-aging formula, especially given that statins prevent rapamycin-induced dyslipidemia.²³

Conclusion: Lessons Learned from Koschei

The creators of fairy tales noticed that the extraordinary longevity is associated with thinness, whereas obese people do not live long. It is not a coincidence that another character of Slavic tales, Baba Yaga the bony leg (kostianaia noga), was extremely old and thin. She cooked potion (зелье), an anti-aging mixture, for Koschei and herself. Now we can compose this mixture by using available drugs. The cornerstone of the formula is a rapalog such as rapamycin. Yet, gerontologists claim that rapamycin cannot be used in humans because of its terrible side effects. This modern tale about side effects of rapamycin might surprise physicians, who have prescribed rapamycin, everalimus to millions of patients worldwide. But practicing doctors do not read basic science papers. Why this misinformation circulates among gerontologists and other basic scientists. May be because Koschei and Baba Yaga were evil and had long curly hair (side effects). Or there are other reasons. I will discuss this in forthcoming article ‘Does mankind deserve rapamycin’.

Conflict of Interest

The author declares no conflict of interest.

1. Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, Chao TH *et al.* Rapamycin protects against high fat diet-induced obesity in C57BL/6 J mice. *J Pharmacol Sci* 2009; **109**: 496–503.
2. Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, Hsu HM *et al.* Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HJL mice. *Basic Clin Pharmacol Toxicol* 2009; **105**: 188–198.

3. Leontieva OV, Paszkiewicz G, Demidenko ZN, Blagosklonny MV. Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. *Cell Death Dis* 2013; **4**: e472.
4. Makki K, Taront S, Molendi-Coste O, Bouchaert E, Neve B, Eury E *et al.* Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. *PLoS One* 2014; **9**: e92684.
5. Rovira J, Marcelo Arellano E, Burke JT, Brault Y, Moya-Rull D, Bañón-Maneus E *et al.* Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. *Transpl Int* 2008; **21**: 992–998.
6. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y *et al.* Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. *Diabetes* 2010; **59**: 1338–1348.
7. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A *et al.* Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. *Br J Pharmacol* 2012; **165**: 2325–2340.
8. Diekmann F, Campistol JM, Rovira J, Budde K, Neumayer HH, Oppenheimer F *et al.* Treatment with sirolimus is associated with less weight gain after kidney transplantation. *Transplantation* 2013; **96**: 480–486.
9. Morrisett JD, Abdel-Fattah G, Hoogveen R, Mitchell E, Ballantyne CM, Pownall HJ *et al.* Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. *J Lipid Res* 2002; **43**: 1170–1180.
10. Chakrabarti P, English T, Shi J, Smas CM, Kandror KV. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. *Diabetes* 2010; **59**: 775–781.
11. Yu Z, Wang R, Fok WC, Coles A, Salmon AB, Perez VI. Rapamycin and dietary restriction induce metabolically distinctive changes in mouse liver. *J Gerontol A Biol Sci Med Sci* 2014; e-pub ahead of print 22 April 2014.
12. Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. *Cell Metab* 2013; **18**: 465–469.
13. Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. *Cell Death Dis* 2013; **4**: e964.
14. Yeh WC, Bierer BE, McKnight SL. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. *Proc Natl Acad Sci USA* 1995; **92**: 11086–11090.
15. Bell A, Grunder L, Sorisky A. Rapamycin inhibits human adipocyte differentiation in primary culture. *Obes Res* 2000; **8**: 249–254.
16. Zhang HH, Huang J, Duvel K, Boback B, Wu S, Squillace RM *et al.* Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. *PLoS One* 2009; **4**: e6189.
17. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. *Aging (Albany NY)* 2009; **1**: 281–288.
18. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. *J Cardiovasc Pharmacol* 2005; **46**: 481–486.
19. Ellosa MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA *et al.* Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. *Am J Transplant* 2003; **3**: 562–569.
20. Chen WQ, Zhong L, Zhang L, Ji XP, Zhang M, Zhao YX *et al.* Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. *Br J Pharmacol* 2009; **156**: 941–951.
21. Liu Y, Diaz V, Fernandez E, Strong R, Ye L, Baur JA *et al.* Rapamycin-induced metabolic defects are reversible in both lean and obese mice. *Aging (Albany NY)* 2014; **6**: 742–754.
22. Fang Y, Bartke A. Prolonged rapamycin treatment led to beneficial metabolic switch. *Aging (Albany NY)* 2013; **5**: 328–329.
23. Legendre C, Campistol JM, Squifflet JP, Burke JT Group. SERTS. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. *Transplant Proc* 2003; **35**: 151S–153S.
24. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in *Drosophila* by modulation of genes in the TOR signaling pathway. *Curr Biol* 2004; **14**: 885–890.
25. Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell* 2006; **124**: 471–484.
26. Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. *Genetics* 2011; **189**: 1177–1201.
27. Howell JJ, Manning BD. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. *Trends Endocrinol Metab* 2011; **22**: 94–102.
28. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL *et al.* With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. *Cell Metab* 2010; **11**: 453–465.
29. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. *Mol Cell* 2010; **40**: 310–322.
30. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol* 2011; **12**: 21–35.
31. Duran RV, Hall MN. Glutaminolysis feeds mTORC1. *Cell Cycle* 2012; **11**: 4107–4108.
32. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. *Endocrinology* 2005; **146**: 1473–1481.

33. Bochkis IM, Shin S, Kaestner KH. Bile acid-induced inflammatory signaling in mice lacking Foxa2 in the liver leads to activation of mTOR and age-onset obesity. *Mol Metab* 2013; **2**: 447–456.
34. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. *J Biol Chem* 2001; **276**: 38052–38060.
35. Um SH, Frigerio F, Watanabe M, Picard F, Joquin M, Sticker M *et al*. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* 2004; **431**: 200–205.
36. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. *Trends Biochem Sci* 2005; **30**: 35–42.
37. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? *Oncogene* 2006; **25**: 6347–6360.
38. Yu Y, Yoon SO, Poulgiannis G, Yang Q, Ma XM, Villen J *et al*. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science* 2011; **332**: 1322–1326.
39. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D *et al*. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science* 2011; **332**: 1317–1322.
40. Einstein FH, Fishman S, Bauman J, Thompson RF, Huffman DM, Atzmon G *et al*. Enhanced activation of a 'nutrient-sensing' pathway with age contributes to insulin resistance. *Faseb J* 2008; **22**: 3450–3457.
41. Mordier S, Iynedjian PB. Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes. *Biochem Biophys Res Commun* 2007; **362**: 206–211.
42. Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW, Ruderman NB. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation? *Cell Cycle* 2011; **10**: 3447–3451.
43. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. *Curr Biol* 2004; **14**: 1650–1656.
44. Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E *et al*. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. *Diabetes* 2005; **54**: 2674–2684.
45. Luong N, Davies CR, Wessells RJ, Graham SM, King MT, Veech R *et al*. Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. *Cell Metab* 2006; **4**: 133–142.
46. Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P *et al*. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. *Diabetes* 2007; **56**: 1600–1607.
47. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA *et al*. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science* 2005; **310**: 1642–1646.
48. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. *Mol Cell Biol* 2006; **26**: 63–76.
49. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? *Transplant Proc* 2009; **41**: S31–S38.
50. Daquinac AC, Tseng C, Salameh A, Zhang Y, Amaya-Manzanares F, Dadbin A *et al*. Depletion of white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity development. *Cell Death Differ* 2014; e-pub ahead of print 24 October 2014; doi:10.1038/cdd.2014.148.
51. Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y *et al*. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. *Cell Death Differ* 2013; **20**: 774–783.
52. Nguyen MT, Csermely P, Soti C. Hsp90 chaperones PPARgamma and regulates differentiation and survival of 3T3-L1 adipocytes. *Cell Death Differ* 2013; **20**: 1654–1663.
53. Nisoli E, Cardile A, Bulbarelli A, Tedesco L, Bracale R, Cozzi V *et al*. White adipocytes are less prone to apoptotic stimuli than brown adipocytes in rodent. *Cell Death Differ* 2006; **13**: 2154–2156.
54. Barth JM, Szabad J, Hafen E, Kohler K. Autophagy in Drosophila ovaries is induced by starvation and is required for oogenesis. *Cell Death Differ* 2011; **18**: 915–924.
55. Cai D, Liu T. Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB. *Aging (Albany NY)* 2012; **4**: 98–115.
56. Fabre O, Breuker C, Amouzou C, Salehzada T, Kitzmann M, Mercier J *et al*. Defects in TLR3 expression and RNase L activation lead to decreased MnSOD expression and insulin resistance in muscle cells of obese people. *Cell Death Dis* 2014; **5**: e1136.
57. Fabre O, Salehzada T, Lambert K, Boo Seok Y, Zhou A, Mercier J *et al*. RNase L controls terminal adipocyte differentiation, lipids storage and insulin sensitivity via CHOP10 mRNA regulation. *Cell Death Differ* 2012; **19**: 1470–1481.
58. Perry RJ, Shulman GI. Treating fatty liver and insulin resistance. *Aging (Albany NY)* 2013; **5**: 791–792.
59. Galbo T, Perry RJ, Nishimura E, Samuel VT, Quistorff B, Shulman GI. PP2A inhibition results in hepatic insulin resistance despite Akt2 activation. *Aging (Albany NY)* 2013; **5**: 770–781.
60. Galbo T, Shulman GI. Lipid-induced hepatic insulin resistance. *Aging (Albany NY)* 2013; **5**: 582–583.
61. Rogers NH, Smith RG. Brown-to-white transition in subcutaneous fat: linking aging and disease. *Aging (Albany NY)* 2012; **4**: 728–729.
62. Leibowitz G, Cerasi E, Ketzinel-Gilad M. The role of mTOR in the adaptation and failure of beta-cells in type 2 diabetes. *Diabetes Obes Metab* 2008; **10**: 157–169.
63. Shigeyama Y, Kobayashi T, Kido Y, Hashimoto N, Asahara S, Matsuda T *et al*. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. *Mol Cell Biol* 2008; **28**: 2971–2979.
64. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM *et al*. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Science* 2012; **335**: 1638–1643.
65. Lamming DW, Ye L, Astle CM, Baur JA, Sabatini DM, Harrison DE. Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive. *Aging Cell* 2013; **12**: 712–718.
66. Blagosklonny MV. Rapamycin-induced glucose intolerance: hunger or starvation diabetes. *Cell Cycle* 2011; **10**: 4217–4224.
67. Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. *Aging (Albany NY)* 2012; **4**: 350–358.
68. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. *Proc Natl Acad Sci USA* 2004; **101**: 6659–6663.
69. Fontana L, Partridge L, Longo VD. Extending healthy life span—from yeast to humans. *Science* 2010; **328**: 321–326.
70. Kennedy BK, Steffen KK, Kaeblerlein M. Ruminations on dietary restriction and aging. *Cell Mol Life Sci* 2007; **64**: 1323–1328.
71. Baur JA, Chen D, Chini EN, Chua K, Cohen HY, de Cabo R *et al*. Dietary restriction: standing up for sirtuins. *Science* 2010; **329**: 1012–1013.
72. Houthoofd K, Gems D, Johnson TE, Vanfleteren JR. Dietary restriction in the nematode *Caenorhabditis elegans*. *Interdiscip Top Gerontol* 2007; **35**: 98–114.
73. Ingram DK, Roth GS, Lane MA, Ottinger MA, Zou S, de Cabo R *et al*. The potential for dietary restriction to increase longevity in humans: extrapolation from monkey studies. *Biogerontology* 2006; **7**: 143–148.
74. Blagosklonny MV. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). *Cell Cycle* 2010; **9**: 683–688.
75. Cava E, Fontana L. Will calorie restriction work in humans? *Aging (Albany NY)* 2013; **5**: 507–514.
76. Mercken EM, Carboneau BA, Krzywick-Walker SM, de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. *Ageing Res Rev* 2012; **11**: 390–398.
77. Jiang N, Du G, Tobias E, Wood JG, Whitaker R, Neretti N *et al*. Dietary and genetic effects on age-related loss of gene silencing reveal epigenetic plasticity of chromatin repression during aging. *Aging (Albany NY)* 2013; **5**: 813–824.
78. Partridge L, Alic N, Bjedov I, Piper MD. Ageing in Drosophila: the role of the insulin/Igf and TOR signalling network. *Exp Gerontol* 2011; **46**: 376–381.
79. Emran S, Yang M, He X, Zandveld J, Piper MD. Target of rapamycin signalling mediates the lifespan-extending effects of dietary restriction by essential amino acid alteration. *Aging (Albany NY)* 2014; **6**: 390–398.
80. Lettieri Barbato D, Tatulli G, Aquilano K, Ciriolo MR. FoxO1 controls lysosomal acid lipase in adipocytes: implication of lipophagy during nutrient restriction and metformin treatment. *Cell Death Dis* 2013; **4**: e861.
81. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K *et al*. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. *Cell Death Dis* 2010; **1**: e10.
82. Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. *Carcinogenesis* 2002; **23**: 817–822.
83. Lefevre M, Redman LM, Heilbronn LK, Smith JV, Martin CK, Rood JC *et al*. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. *Atherosclerosis* 2008; **203**: 206–213.
84. Colman RJ, Beasley TM, Allison DB, Weindruch R. Attenuation of sarcopenia by dietary restriction in rhesus monkeys. *J Gerontol A Biol Sci Med Sci* 2008; **63**: 556–559.
85. Fontana L, Klein S, Holloszy J. Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. *Age (Dordr)* 2010; **32**: 97–108.
86. Ye L, Widlund AL, Sims CA, Lamming DW, Guan Y, Davis JG *et al*. Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance. *Aging (Albany NY)* 2013; **5**: 539–550.
87. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. *Aging Cell* 2014; **13**: 616–622.
88. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semchenko AV, Tyndyk ML *et al*. Rapamycin extends maximal lifespan in cancer-prone mice. *Am J Pathol* 2010; **176**: 2092–2097.
89. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semchenko AV, Tyndyk ML *et al*. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. *Cell Cycle* 2011; **10**: 4230–4236.

90. Popovich IG, Anisimov VN, Zabezhinski MA, Semchenko AV, Tyndyk ML, Yurova MN *et al.* Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. *Cancer Biol Ther* 2014; **15**: 586–592.
91. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV *et al.* New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53 – / – mice by delaying carcinogenesis. *Aging (Albany NY)* 2012; **4**: 715–722.
92. Kondratov RV, Kondratova AA. Rapamycin in preventive (very low) doses. *Aging (Albany NY)* 2014; **6**: 158–159.
93. Khapre RV, Kondratova AA, Patel S, Dubrovsky Y, Wrobel M, Antoch MP *et al.* BMAL1-dependent regulation of the mTOR signaling pathway delays aging. *Aging (Albany NY)* 2014; **6**: 48–57.
94. Ye L, Varamini B, Lamming DW, Sabatini DM, Baur JA. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. *Front Genet* 2012; **3**: 177.
95. Leontieva OV, Demidenko ZN, Blagosklonny MV. Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. *Cell Death Dis* 2014; **5**: e1214.
96. Law BK. Rapamycin: an anti-cancer immunosuppressant? *Crit Rev Oncol Hematol* 2005; **56**: 47–60.
97. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM *et al.* Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. *J Am Soc Nephrol* 2006; **17**: 581–589.
98. Blagosklonny MV. Prevention of cancer by inhibiting aging. *Cancer Biol Ther* 2008; **7**: 1520–1524.
99. Paoletti E, Cannella G. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin. *Transplant Proc* 2012; **44**: S41–S43.
100. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX *et al.* Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. *Cell Death Dis* 2012; **3**: e275.
101. Airiau K, Mahon FX, Josselin M, Jeanneteau M, Belloc F. PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor. *Cell Death Dis* 2013; **4**: e827.
102. Chang L, Graham PH, Hao J, Ni J, Buccì J, Cozzi PJ *et al.* PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. *Cell Death Dis* 2014; **5**: e1437.
103. Ng TL, Leprivier G, Robertson MD, Chow C, Martin MJ, Laderoute KR *et al.* The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. *Cell Death Differ* 2011; **19**: 501–510.
104. Chang L, Graham PH, Hao J, Ni J, Buccì J, Cozzi PJ *et al.* Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. *Cell Death Dis* 2013; **4**: e875.
105. Francipane MG, Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. *Oncotarget* 2013; **4**: 1948–1962.
106. Cufi S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, Lopez IA *et al.* Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. *Oncotarget* 2013; **4**: 1484–1495.
107. Reikvam H, Nepstad I, Bruserud O, Hatfield KJ. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. *Oncotarget* 2013; **4**: 830–843.
108. Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A *et al.* A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. *Oncotarget* 2012; **3**: 1615–1628.
109. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D *et al.* Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. *Oncotarget* 2012; **3**: 371–394.
110. Blagosklonny MV, Hall MN. Growth and aging: a common molecular mechanism. *Aging (Albany NY)* 2009; **1**: 357–362.
111. Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. *Cell Cycle* 2010; **9**: 3151–3156.
112. Blagosklonny MV. Aging is not programmed: genetic pseudo-program is a shadow of developmental growth. *Cell Cycle* 2013; **12**: 3736–3742.
113. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K *et al.* Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 2009; **460**: 392–396.
114. Spong A, Bartke A. Rapamycin slows aging in mice. *Cell Cycle* 2012; **11**: 845.
115. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE *et al.* Rapamycin slows aging in mice. *Aging Cell* 2012; **11**: 675–682.
116. Blagosklonny MV. Rapamycin extends life- and health span because it slows aging. *Aging (Albany NY)* 2013; **5**: 592–598.
117. Zhang Y, Bokov A, Gelfond J, Soto V, Ikono Y, Hubbard G *et al.* Rapamycin extends life and health in C57BL/6 mice. *J Gerontol A Biol Sci Med Sci* 2013; **69**: 119–130.
118. Robida-Stubbs S, Glover-Cutter K, Lamming DW, Mizunuma M, Narasimhan SD, Neumann-Haefelin E *et al.* TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. *Cell Metab* 2012; **15**: 713–724.
119. Blagosklonny MV. Answering the ultimate question 'what is the proximal cause of aging?'. *Aging (Albany NY)* 2012; **4**: 861–877.
120. Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V *et al.* Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. *PLoS One* 2013; **9**: e83988.
121. Hinojosa CA, Mgbemena V, Van Roekel S, Austad SN, Miller RA, Bose S *et al.* Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence. *Exp Gerontol* 2012; **47**: 958–965.
122. Leontieva OV, Demidenko ZN, Blagosklonny MV. S6K in geroconversion. *Cell Cycle* 2013; **12**: 3249–3252.
123. Leontieva OV, Blagosklonny MV. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. *Cell Cycle* 2013; **12**: 3063–3069.
124. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. *Proc Natl Acad Sci USA* 2012; **109**: 13314–13318.
125. Leontieva OV, Demidenko ZN, Blagosklonny MV. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. *Proc Natl Acad Sci USA* 2014; **111**: 8832–8837.
126. Leontieva OV, Demidenko ZN, Blagosklonny MV. MEK drives cyclin D1 hyperlevelation during geroconversion. *Cell Death Differ* 2013; **20**: 1241–1249.
127. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB *et al.* mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. *Cell Stem Cell* 2012; **11**: 401–414.
128. Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. *Cell Cycle* 2012; **11**: 2391–2401.
129. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG *et al.* Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. *Am J Pathol* 2012; **181**: 278–293.
130. Luo Y, Li L, Zou P, Wang J, Shao L, Zhou D *et al.* Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence. *Transplantation* 2014; **97**: 20–29.
131. Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D *et al.* DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. *J Cell Sci* 2011; **124**: 68–81.
132. Tchoknia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. *J Clin Invest* 2013; **123**: 966–972.
133. Halicka HD, Zhao H, Li J, Lee YS, Hsieh TC, Wu JM *et al.* Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. *Aging (Albany NY)* 2012; **4**: 952–965.
134. Narita M, Young AR, Arakawa S, Samarajiva SA, Nakashima T, Yoshida S *et al.* Spatial coupling of mTOR and autophagy augments secretory phenotypes. *Science* 2011; **332**: 966–970.
135. Pani G. From growing to secreting: new roles for mTOR in aging cells. *Cell Cycle* 2011; **10**: 2450–2453.
136. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? *Aging (Albany NY)* 2012; **4**: 450–455.
137. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. *Trends Mol Med* 2007; **13**: 252–259.
138. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. *Curr Opin Genet Dev* 2013; **23**: 53–62.
139. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK *et al.* RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. *Cancer Res* 2007; **67**: 2408–2413.
140. Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD *et al.* Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. *Clin Cancer Res* 2007; **13**: 2281–2289.
141. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV *et al.* Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53 +/– mice. *Aging (Albany NY)* 2012; **4**: 709–714.
142. Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. *Aging (Albany NY)* 2012; **4**: 660–661.
143. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C *et al.* Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. *Aging (Albany NY)* 2013; **5**: 100–110.
144. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? *Cancer Biol Ther* 2012; **13**: 1349–1354.
145. Blagosklonny MV. Immunosuppressants in cancer prevention and therapy. *Oncoimmunology* 2013; **2**: e26961.
146. Selman C, Partridge L. A double whammy for aging? Rapamycin extends lifespan and inhibits cancer in inbred female mice. *Cell Cycle* 2012; **11**: 17–18.

147. Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. *Am J Pathol* 2012; **181**: 1142–1146.
148. Tsang CK, Qi H, Liu LF, and Zheng XFS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. *Drug Disc Today* 2007; **12**: 112–124.
149. Zheng XF. Chemoprevention of age-related macular degeneration (AMD) with rapamycin. *Aging (Albany NY)* 2012; **4**: 375–376.
150. Dazert E, Hall MN. mTOR signaling in disease. *Curr Opin Cell Biol* 2011; **23**: 744–755.
151. Johnson SC, Rabinovitch PS, Kaeblerlein M. mTOR is a key modulator of ageing and age-related disease. *Nature* 2013; **493**: 338–345.
152. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ *et al.* Late life rapamycin treatment reverses age-related heart dysfunction. *Aging Cell* 2013; **12**: 851–862.
153. Johnson SC, Yanos ME, Kayser EB, Quintana A, Sangsland M, Castanza A *et al.* mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. *Science* 2013; **342**: 1524–1528.
154. Glynn EL, Lujan HL, Kramer VJ, Drummond MJ, DiCarlo SE, Rasmussen BB. A chronic increase in physical activity inhibits fed-state mTOR/S6K1 signaling and reduces IRS-1 serine phosphorylation in rat skeletal muscle. *Appl Physiol Nutr Metab* 2008; **33**: 93–101.
155. Dilman VM, Berstein LM, Zabezhinski MA, Alexandrov VA, Bobrov JF, Pliss GB. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. *Arch Geschwulstforsch* 1978; **48**: 1–8.
156. Dilman VM, Anisimov VN. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. *Gerontology* 1980; **26**: 241–246.
157. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA *et al.* Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. *Exp Gerontol* 2005; **40**: 685–693.
158. Anisimov VN, Egormin PA, Bershtein LM, Zabezhinski MA, Piskunova TS, Popovich IG *et al.* Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. *Bull Exp Biol Med* 2005; **139**: 721–723.
159. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA *et al.* Metformin slows down aging and extends life span of female SHR mice. *Cell Cycle* 2008; **7**: 2769–2773.
160. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M *et al.* Metformin improves healthspan and lifespan in mice. *Nat Commun* 2013; **4**: 2192.
161. Moiseeva O, Deschenes-Simard X, Pollak M, Ferbeyre G. Metformin, aging and cancer. *Aging (Albany NY)* 2013; **5**: 330–331.
162. Anisimov VN. Metformin: do we finally have an anti-aging drug? *Cell Cycle* 2013; **12**: 3483–3489.
163. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A *et al.* Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. *Cell Death Dis* 2011; **2**: e199.
164. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. *Cell Cycle* 2006; **5**: 2087–2102.
165. Leontieva OV, Blagosklonny MV. mTOR of pseudo-hypoxic state in aging: rapamycin to the rescue. *Cell Cycle* 2014; **13**: 509–515.
166. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005; **330**: 1304–1305.
167. Koch L. Cancer: long-term use of metformin could protect against breast cancer. *Nat Rev Endocrinol* 2010; **6**: 356.
168. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care* 2009; **32**: 1620–1625.
169. Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. *Future Oncol* 2010; **6**: 1313–1323.
170. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. *Cancer Prev Res (Phila)* 2010; **3**: 1066–1076.
171. Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. *Am J Med Sci* 2008; **336**: 241–247.
172. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. *J Alzheimers Dis* 2014; **41**: 61–68.
173. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. *Cancer Discov* 2012; **2**: 778–790.
174. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G *et al.* Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. *Diabetes Care* 2011; **34**: 2323–2328.
175. Bulckaen H, Prevost G, Boulanger E, Robitaille G, Roquet V, Gaxatte C *et al.* Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. *Am J Physiol Heart Circ Physiol* 2008; **294**: H1562–H1570.
176. Phillips T, Leeuwenburgh C. Lifelong aspirin supplementation as a means to extending life span. *Rejuvenation Res* 2004; **7**: 243–251.
177. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S *et al.* Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet* 2011; **378**: 2081–2087.
178. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K *et al.* Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. *Gastroenterology* 2012; **142**: 1504–1515 e1503.
179. Strong R, Miller RA, Astle CM, Floyd RA, Flurkey K, Hensley KL *et al.* NORDIHYDROGUAIARETIC acid and aspirin increase lifespan of genetically heterogeneous male mice. *Aging Cell* 2008; **7**: 641–650.
180. Renna NF, Vazquez MA, Lama MC, Gonzalez ES, Miatello RM. Effect of chronic aspirin administration on an experimental model of metabolic syndrome. *Clin Exp Pharmacol Physiol* 2009; **36**: 162–168.
181. Chang ET, Froslev T, Sorensen HT, Pedersen L. A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark. *Br J Cancer* 2011; **105**: 1776–1782.
182. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. *Lancet* 2007; **369**: 1603–1613.
183. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL *et al.* Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. *J Natl Cancer Inst* 2009; **101**: 267–276.
184. Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. *Oncotarget* 2012; **3**: 893–906.
185. Wan QL, Zheng SQ, Wu GS, Luo HR. Aspirin extends the lifespan of *Caenorhabditis elegans* via AMPK and DAF-16/FOXO in dietary restriction pathway. *Exp Gerontol* 2013; **48**: 499–506.
186. Eguchi S, Iwasaki H, Ueno H, Frank GD, Motley ED, Eguchi K *et al.* Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. *J Biol Chem* 1999; **274**: 36843–36851.
187. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M *et al.* Protective effect of the inhibition of the renin-angiotensin system on aging. *Regul Pept* 2005; **128**: 247–252.
188. Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F. Protective effect of long-term angiotensin II inhibition. *Am J Physiol Heart Circ Physiol* 2007; **293**: H1351–H1358.
189. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M *et al.* Disruption of the Ang II type 1 receptor promotes longevity in mice. *J Clin Invest* 2009; **119**: 524–530.
190. Linz W, Heitsch H, Scholkens BA, Wiemer G. Long-term angiotensin II type 1 receptor blockade with fosartan doubles lifespan of hypertensive rats. *Hypertension* 2000; **35**: 908–913.
191. Linz W, Jessen T, Becker RH, Scholkens BA, Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. *Circulation* 1997; **96**: 3164–3172.
192. Santos EL, de Picoli Souza K, da Silva ED, Batista EC, Martins PJ, D'Almeida V *et al.* Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. *Biochem Pharmacol* 2009; **78**: 951–958.
193. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW *et al.* Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. *Am J Cardiol* 2011; **107**: 1028–1033.
194. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. *J Clin Oncol* 2011; **29**: 2635–2644.
195. London WT, McGlynn KA. Can propranolol prevent hepatocellular carcinoma? *Cancer Prev Res (Phila)* 2012; **5**: 989–991.
196. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO *et al.* Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. *Oncotarget* 2010; **1**: 628–638.
197. Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? *Oncotarget* 2010; **1**: 466–469.
198. Ghosh PM, Shu ZJ, Zhu B, Lu Z, Ikono Y, Barnes JL *et al.* Role of beta-adrenergic receptors in regulation of hepatic fat accumulation during aging. *J Endocrinol* 2013; **213**: 251–261.
199. Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. *Am J Cardiol* 2006; **98**: 923–928.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International Licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0>